{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-045557","form_type":"8-K","ticker":"CYRX","cik":"0001124524","company_name":"Cryoport, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.586654+00:00","generated_at":"2026-05-22T07:01:59.447991+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"medium","headline":"Cryoport Q1 revenue $41M, up 10% YoY; cell & gene therapy revenue up 33%","bullets":["Commercial Cell & Gene therapy revenue $7.2M, up 33% YoY; supported 19 commercial therapies.","Life Sciences Services revenue $22.9M (+17%); Products $18.2M (+2%); total continuing ops $41.0M.","Strategic DHL partnership; CRYOPDP divestiture expected Q2/Q3 2025, providing capital infusion.","Supported 711 global clinical trials (net +36 YoY); 79 Phase 3; six BLA/MAA filings in Q1.","Abeona's ZEVASKYN FDA-approved post-Q1; 17 more application filings anticipated in 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-045557","json":"https://secwatch.observer/filing/0001104659-25-045557.json","markdown":"https://secwatch.observer/filing/0001104659-25-045557.md","text":"https://secwatch.observer/filing/0001104659-25-045557.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1124524/000110465925045557/0001104659-25-045557-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1124524/000110465925045557/tm2514334d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T07:01:59.447991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}